Sustained-release and instant-release verapamil in treatment of angina pectoris
- 55 Downloads
The efficacy of a sustained-release preparation of verapamil (verapamil-IR) has been compared with that of a conventional instant-release formulation (verapamil-IR) in 10 patients with stable angina pectoris treated for 3 weeks with both preparations.
The diurnal serum concentrations of verapamil and norverapamil did not differ significantly during treatment with verapamil-IR 120 mg t.i.d. and verapamil-SR 360 mg once daily, but verapamil-SR 240 mg produced significantly lower serum concentrations. The differences did not affect the exercise capacity or the occurrence of ST-segment depression during maximal exercise.
Verapamil-SR was well tolerated. A multiple instant-release dosage regime can now be replaced by once daily administration of the sustained-release preparation.
Key wordsverapamil angina pectoris sustained-release formulations serum levels
Unable to display preview. Download preview PDF.
- 1.Anderson P (1986) Pharmacokinetics of calcium channel blocking agents. Acta Pharmacol Toxicol 58 [Suppl 2]: 43–57Google Scholar
- 2.Lim CK, Rideout JM, Sheldon JWS (1983) Determination of verapamil and norverapamil in serum by high-performance liquid chromatography. J Liquid Chromatogr 6: 877–893Google Scholar
- 3.Kohli RS, Rodrigues EA, Hughes LO, Lahiri A, Raftery EB (1987) Sustained-release verapamil, a once-daily preparation: Objective evaluation using exercise testing, ambulatory monitoring and blood levels in patients with stable angina. J Am Coll Cardiol 9: 615–621Google Scholar
- 4.Rodrigues EA, DasGupta P, Hains ADB, Raftery EB (1988) An objective evaluation of once-daily sustained-release verapamil (480 mg) in chronic stable angina. Eur J Clin Pharmacol 34: 531–532Google Scholar
- 5.Midtbø K, Hals O, Van der Meer J, Storstein L, Lauve O (1986) Instant and sustained-release verapamil in treatment of essential hypertension. Am J Cardiol 57D–59DGoogle Scholar
- 6.Mølgaard H, Bjerregaard P, Jørgensen HS, Klitgaard NA (1987) A comparison of the 24-hour antiarrhythmic effect of verapamil, given in conventional and a new slow-release formulation in patients with chronic atrial fibrillation. Eur J Clin Pharmacol 33: 447–453Google Scholar
- 7.Follath F, Schutz E, Bühler F (1986) Pharmacokinetics of conventional and slow-release verapamil. Br J Clin Pharmacol 21: 149S-153SGoogle Scholar